文献速递慢性肾脏病

胰高血糖素样肽-1受体激动剂司美格鲁肽降低血红蛋白A1c独立于基线估算肾小球滤过率:SUSTAIN与PIONEER项目的事后分析

Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs.
PubMed 文献 · Kidney Int Rep · 2022-08-03

本事后分析评估司美格鲁肽在SUSTAIN 4-6、10(皮下)和PIONEER 5、6(口服)试验中不同基线估算肾小球滤过率亚组的降糖疗效。共纳入8859例参与者,各试验经对照校正的HbA1c降幅为0.6%至1.6%个百分点,各eGFR亚组间相似(交互P值≥0.33)。结论认为司美格鲁肽的降HbA1c效果不随eGFR变化。

要点

  • 司美格鲁肽降低HbA1c的疗效在基线eGFR>15 ml/min/1.73 m²的各亚组间相似。
  • 各试验经对照校正的HbA1c降幅为0.6%至1.6%个百分点。
  • 在多数eGFR亚组中司美格鲁肽较对照带来更大体重下降,未发现新的安全性问题。

核心结论

  • 在eGFR>15 ml/min/1.73 m²的2型糖尿病参与者中,司美格鲁肽的降HbA1c效果不随eGFR变化。

研究设计与样本

  • SUSTAIN 4-6和10(皮下司美格鲁肽)及PIONEER 5和6(口服司美格鲁肽)临床试验的事后分析,共纳入8859例参与者。
  • 按基线eGFR亚组评估从基线至治疗结束的HbA1c和体重变化,并评估不良事件。

主要发现

  • 各试验经对照校正的HbA1c降幅为0.6%至1.6%个百分点,各eGFR亚组间相似(交互P值≥0.33)。
  • 在几乎全部基线eGFR亚组中,司美格鲁肽较对照带来更大体重下降。
  • 在SUSTAIN 6和10及PIONEER 5和6中,较低eGFR亚组的体重下降名义上大于较高eGFR亚组(交互P<0.05)。
  • 未发现司美格鲁肽新的安全性问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for reducing hemoglobin A1c (HbA1c) in people with type 2 diabetes (T2D), including those with reduced kidney function. METHODS: This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a GLP-1RA, in participants with a range of kidney functions in the SUSTAIN 4-6 and 10 (subcutaneous semaglutide) and PIONEER 5 and 6 (oral semaglutide) clinical trials. Trial-level changes from baseline to end of treatment (EOT) in HbA1c and body weight (BW) were assessed in participants with estimated glomerular filtration rate (eGFR) >15 ml/min per 1.73 m2 by subgroups categorized according to baseline eGFR. Adverse events were also evaluated. RESULTS: The analysis included 8859 participants. The mean comparator-adjusted reduction in HbA1c from baseline to EOT with semaglutide ranged from 0.6% to 1.6% points across trials, with similar reductions across the eGFR subgroups (interaction P-value ≥ 0.33 for difference between eGFR subgroups within each trial). Greater weight loss from baseline to EOT with semaglutide versus comparator was observed across almost all baseline eGFR subgroups, with nominally greater weight loss with lower versus higher eGFR in SUSTAIN 6 and 10 and PIONEER 5 and 6 (interaction P < 0.05). No new safety concerns with semaglutide were identified. CONCLUSION: The HbA1c-lowering effect of semaglutide in participants with T2D was comparable irrespective of eGFR, which ranged upwards from eGFR >15 ml/min per 1.73 m2.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Cherney DZI, Hadjadj S, Lawson J, et al. Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. Kidney Int Rep. 2022. PMID: 36531884. doi:10.1016/j.ekir.2022.07.167

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。